Feb 20 |
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
|
Feb 12 |
TENX: First Patient Enrolled
|
Feb 8 |
Tenax Therapeutics stock sinks after it prices its public offering
|
Feb 8 |
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
|
Feb 8 |
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
|
Feb 7 |
What's Going On With Tenax Therapeutics Shares?
|
Feb 6 |
Nasdaq Down 50 Points; Willis Towers Watson Posts Upbeat Profit
|
Feb 6 |
Tenax surges after patent win for heart failure therapy
|
Feb 6 |
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
|